Dermal endothelial cells express eotaxin in hypereosinophilic syndrome

Journal of the American Academy of Dermatology

Volumn 49, Issue 5, 2003, Pages 918-921

  Tsunemi, Yuichiro ^a   Idezuki, Takeo ^b   Nakamura, Koichiro ^b   Tamaki, Kunihiko ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; PREDNISOLONE; STEROID;

AGED; ARTICLE; CASE REPORT; CELL COUNT; CELL MIGRATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN BIOPSY; SKIN CELL; SKIN MANIFESTATION; TREATMENT FAILURE;

EID: 0142244816     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)00449-3     Document Type: Article

References (21)

1. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med 1968;68:1220-9.
2. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine 1975;54:1-27.
3. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982;97:78-92.
4. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79:3101-9.
5. Owen WF, Rothenberg ME, Petersen J, Weller PF, Silberstein D, Sheffer AL, et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 1989;170:343-8.
6. Enokihara H, Kajitani H, Nagashima S, Tsunogake S, Takano N, Saito K, et al. Interleukin 5 activity in sera from patients with eosinophilia. Br J Haematol 1990;75:458-62.
7. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994;330:535-8.
8. Tai PC, Spry CJF, Peterson C, Venge P, Olsson I. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature 1984;309:182-4.
9. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759-79.
10. Gleich GJ, Frigas E, Loegering DA, Wassom DL, Steinmuller D. Cytotoxic properties of the eosinophil major basic protein. J Immunol 1979;123:2925-7.
11. Young JDE, Peterson CGB, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986;321:613-6.
12. Butterworth AE, David JR. Current concepts: eosinophil function. N Engl J Med 1981;304:154-6.
13. Nakamura K, Ootsuki M, Furue M, Nakagawa H, Tamaki K, Ishibashi Y. Hypereosinophilic syndrome which mimicked allergic granulomatous angitis. Rinsho Derma (Tokyo) 1996;38:1639-42.
14. Gyotoku E, Hihara S, Mihara S, Koro O, Yamamoto S. Hypereosinophilic syndrome. Rinsho Derma (Tokyo) 1997;39:2031-4.
15. Aractingi S, Janin A, Zini JM, Gauthier MS, Chauvenet L, Tobelem G, et al. Specific mucosal erosions in hypereosinophilic syndrome: evidence for eosinophil protein deposition. Arch Dermatol 1996;132:535-41.
16. Wakugawa M, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H, et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol 2000;143:112-6.
17. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
18. Sanz MJ, Ponath PD, Mackay CR, Newman W, Miyasaka M, Tamatani T, et al. Human eotaxin induces alpha4 and beta2 integrin-dependent eosinophil accumulation in rat skin in vivo: delayed generation of eotaxin in response to IL-4. J Immunol 1998;160:3569-76.
19. Rollins BJ. Chemokines. Blood 1997;90:909-28.
20. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27:3507-16.
21. Collins PD, Marleau S, Griffiths-Johnson DA, Joe PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182:1169-74.